AEROSPAN drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.
OVERDOSAGE
In a double-blind, placebo-controlled study, 18 mg of flunisolide was administered via the CFC formulation over a three-hour period (nine times the maximum labeled daily dose) in 94 patients with acute asthma, and no clinically deleterious effects were observed.
CONTRAINDICATIONS
AEROSPAN Inhalation Aerosol is contraindicated in the following conditions:
Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.